Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CervoMed ( (CRVO) ) just unveiled an update.
On April 22, 2026, CervoMed reported Phase 2b RewinD-LB trial data presented at the American Academy of Neurology meeting showing that neflamapimod increased basal forebrain volume and enhanced functional connectivity in patients with dementia with Lewy bodies. The placebo-controlled MRI analyses indicated a statistically significant increase in right basal forebrain volume and subsequent gains in right basal forebrain–default mode network connectivity, results that align with preclinical data and prior Alzheimer’s findings and suggest neflamapimod may act on underlying disease mechanisms in DLB, while also positioning basal forebrain MRI as a promising biomarker and supporting the company’s plan, subject to financing, to advance to Phase 3.
The most recent analyst rating on (CRVO) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
Spark’s Take on CRVO Stock
According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and worsening cash burn) and a bearish technical setup (price below key moving averages and negative MACD). Offsetting this, recent positive clinical/program events provide meaningful pipeline momentum, while valuation inputs are largely neutral due to negative earnings and no dividend.
To see Spark’s full report on CRVO stock, click here.
More about CervoMed
CervoMed Inc., listed on Nasdaq under the ticker CRVO, is a clinical-stage biopharmaceutical company focused on neurodegenerative disorders such as dementia with Lewy bodies (DLB), Alzheimer’s disease and other brain conditions. Its lead investigational product, neflamapimod, is an orally administered p38 MAP kinase inhibitor designed to cross the blood-brain barrier, target neuroinflammation and synaptic dysfunction, and potentially slow or reverse disease progression.
Average Trading Volume: 79,482
Technical Sentiment Signal: Sell
Current Market Cap: $36.76M
For detailed information about CRVO stock, go to TipRanks’ Stock Analysis page.